Jeffrey R Vitt, Roger C Cheng, Jason Chung, Travis Caton, Bo Zhou, Nerissa Ko, Karl Meisel, Edilberto Amorim
{"title":"The clinical impact of recent amphetamine exposure in aneurysmal subarachnoid hemorrhage patients.","authors":"Jeffrey R Vitt, Roger C Cheng, Jason Chung, Travis Caton, Bo Zhou, Nerissa Ko, Karl Meisel, Edilberto Amorim","doi":"10.3389/fneur.2024.1480401","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Amphetamines possess sympathomimetic properties that can affect cerebral vasculature though conflicting reports exist about their effect on vasospasm risk and clinical outcomes in aneurysmal subarachnoid hemorrhage. This study aimed to characterize the impact of recent amphetamine use on vasospasm development in aneurysmal subarachnoid hemorrhage as well as neurological outcomes.</p><p><strong>Methods: </strong>We retrospectively screened 441 consecutive patients admitted with a diagnosis of subarachnoid hemorrhage who underwent at least one cerebral digital subtraction angiogram. Patients were excluded if no urinary toxicology screen was performed within 24 h of admission, if there was a diagnosis of non-aneurysmal subarachnoid hemorrhage, or if ictus was greater than 72 h from hospital admission. Vasospasm characteristics were collected from digital subtraction angiography and transcranial Doppler studies.</p><p><strong>Results: </strong>129 patients were included and 24 tested positive for amphetamines on urine drug screen. No significant differences were found in respect to patient age, sex, or admission clinical severity scales (Hunt-Hess and modified Fisher) based on amphetamine use. There was no difference in the severity of vasospasm or time to peak severity based on recent amphetamine use. A trend toward more isolated posterior circulation vasospasm was observed in the amphetamine present group (16.7% vs. 4.8%, <i>p</i> = 0.06), while there was higher incidence of anterior circulation vasospasm in the amphetamine absent group (79.2% vs. 94.3%, <i>p</i> = 0.03). There was no difference in delayed cerebral ischemia incidence, length of hospital stay, need for ventriculoperitoneal shunt placement, functional outcome at discharge or hospital mortality based on amphetamine use.</p><p><strong>Interpretation: </strong>Recent amphetamine use was not associated with worse vasospasm severity or delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage patients. Further investigations about localized effects in the posterior circulation and impact on long-term functional outcomes are warranted.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1480401"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11746030/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fneur.2024.1480401","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Amphetamines possess sympathomimetic properties that can affect cerebral vasculature though conflicting reports exist about their effect on vasospasm risk and clinical outcomes in aneurysmal subarachnoid hemorrhage. This study aimed to characterize the impact of recent amphetamine use on vasospasm development in aneurysmal subarachnoid hemorrhage as well as neurological outcomes.
Methods: We retrospectively screened 441 consecutive patients admitted with a diagnosis of subarachnoid hemorrhage who underwent at least one cerebral digital subtraction angiogram. Patients were excluded if no urinary toxicology screen was performed within 24 h of admission, if there was a diagnosis of non-aneurysmal subarachnoid hemorrhage, or if ictus was greater than 72 h from hospital admission. Vasospasm characteristics were collected from digital subtraction angiography and transcranial Doppler studies.
Results: 129 patients were included and 24 tested positive for amphetamines on urine drug screen. No significant differences were found in respect to patient age, sex, or admission clinical severity scales (Hunt-Hess and modified Fisher) based on amphetamine use. There was no difference in the severity of vasospasm or time to peak severity based on recent amphetamine use. A trend toward more isolated posterior circulation vasospasm was observed in the amphetamine present group (16.7% vs. 4.8%, p = 0.06), while there was higher incidence of anterior circulation vasospasm in the amphetamine absent group (79.2% vs. 94.3%, p = 0.03). There was no difference in delayed cerebral ischemia incidence, length of hospital stay, need for ventriculoperitoneal shunt placement, functional outcome at discharge or hospital mortality based on amphetamine use.
Interpretation: Recent amphetamine use was not associated with worse vasospasm severity or delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage patients. Further investigations about localized effects in the posterior circulation and impact on long-term functional outcomes are warranted.
背景:安非他明具有拟交感神经特性,可影响脑血管系统,但关于其对动脉瘤性蛛网膜下腔出血血管痉挛风险和临床结局的影响存在矛盾的报道。本研究旨在描述近期安非他命使用对动脉瘤性蛛网膜下腔出血血管痉挛发展的影响以及神经预后。方法:我们回顾性筛选了441例连续确诊为蛛网膜下腔出血并接受至少一次脑数字减影血管造影的患者。如果在入院后24 h内未进行尿毒理学筛查,如果诊断为非动脉瘤性蛛网膜下腔出血,或者入院后痉挛大于72 h,则排除患者。通过数字减影血管造影和经颅多普勒检查收集血管痉挛特征。结果:本组共纳入129例患者,尿药筛查安非他明阳性24例。未发现患者年龄、性别或基于安非他明使用的入院临床严重程度量表(Hunt-Hess和修改后的Fisher)有显著差异。血管痉挛的严重程度和达到严重程度高峰的时间与最近使用安非他明的人没有差别。安非他明存在组有更孤立性后循环血管痉挛的趋势(16.7% vs. 4.8%, p = 0.06),而安非他明不存在组前循环血管痉挛的发生率更高(79.2% vs. 94.3%, p = 0.03)。在延迟性脑缺血发生率、住院时间、放置脑室-腹膜分流器的需要、出院时的功能结局或基于安非他明使用的住院死亡率方面没有差异。解释:动脉瘤性蛛网膜下腔出血患者近期使用安非他明与血管痉挛严重程度加重或脑缺血延迟无关。对后循环的局部影响和对长期功能结果的影响的进一步研究是有必要的。
期刊介绍:
The section Stroke aims to quickly and accurately publish important experimental, translational and clinical studies, and reviews that contribute to the knowledge of stroke, its causes, manifestations, diagnosis, and management.